The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea.
Increasing levels of bacterial antibiotic resistance raise the need to assess the eradication efficiency of Helicobacter pylori. The aim of this study was to evaluate 7-year changes in efficacy of one-week first line and second line therapies in Helicobacter pylori eradication rates in Korea. From 2001 to 2007, 4198 Helicobacter pylori-positive patients received first-line therapy (proton pump inhibitor, amoxicillin 1,000 mg b.i.d., and clarithromycin 500 mg b.i.d.). Four hundred ninety patients received second-line therapy (proton pump inhibitor twelve hourly, metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., and bismuth 300 mg q.i.d.). A 13C-urea breath test was used to determine the eradication rate. The eradication rates of first-line therapy were 81.3%, 83.7%, 80.1%, 80.7%, 82.0%, 75.9%, and 77.5% from 2001 to 2007, with a decreasing trend (p < 0.01). The eradication rate of second-line therapy was 77.3%, 86.2%, 95.6%, 95.9%, 89.6%, 83.2%, and 86.4% from 2001 to 2007 without decreasing trend (p = 0.26). The eradication rate of first-line therapy has decreased in the last 7 years while that of second-line therapy has remained the same. A new strategy is required to improve the first-line therapy for Helicobacter pylori eradication in Korea.